Is a low-cost anti-inflammatory drug such as colchicine associated with improved overall patient well-being status? This was the central question in a sub-study of the Australian COPS randomized clinical trial published in this issue of the journal . Functional status, symptom burden, and quality of life were evaluated using two validated metrics in coronary artery disease (CAD) and percutaneous coronary intervention (PCI) cohorts: the 5 Level European Quality of Life 5 Dimensions score (EQ-5D-5L) and the full version of the Seattle Angina Questionnaire (SAQ). They observed improvements in quality of life from baseline to 12 months for the EQ-5D-5L Visual Analogue Scale (VAS) and index score; and SAQ anginal stability, anginal frequency, and disease perception. Although colchicine did not significantly improve a mean change in quality of life, a categorical analysis revealed that patients in the colchicine treatment group experienced a clinically significant improvement in SAQ physical limitation scores.